Merck's COVID pill is last choice for U.S. patients, global

By Deena Beasley (Reuters) - Merck & Co's new antiviral pill, once touted as a potential game changer for treating COVID-19, is the last choice among ...

Related Keywords

New York , United States , Philippines , Milan , Lombardia , Italy , United Kingdom , New Delhi , Delhi , India , London , City Of , Manila , Bangladesh , Mumbai , Maharashtra , Massachusetts , Dhaka , France , Plattsburgh , The Philippines , Ambrish Mithal , Steve Moore , Eliav Barr , Emilio Parodi , Ruma Paul , Sayedur Rahman , Los Angeles , Ridgeback Biotherapeutics , Neha Arora , Alistair Smout , Onisis Stefas , Jim Mangia , Deena Beasley , Tara Vijayan , Neil Jerome Morales , Caroline Humer , Rajesh Gandhi , Glaxosmithkline , Bangabandhu Sheikh Mujib Medical University , Us Department Of Health , Northwell Health , Human Services , Us National Institutes Of Health , Merck Co , Department Of Pharmacology , Gilead Sciences Inc , Reuters , Pfizer , Pfizer Inc , Family Center , Well Child , Central Los , Wall Street , Condo Pharmacy , Bangabandhu Sheikh Mujib Medical , Max Healthcare , Massachusetts General , Los Angeles County , New York State , Chief Pharmacy Officer Onisis Stefas , Reporting By Deena Beasley , Michael Erman , Bill Berkrot , ,